《新股消息》医渡科技(02158.HK)公开超购近1,633倍及上限定价 一手中签率20%
医渡科技(02158.HK)公布招股结果,公布计划全球发售1.56亿股原定10%於本港公开发售,公开发售录超购1,632.84倍,经重新分配後,公开发售股数增至50%,国际发售项下初步提呈发售的发售股份已获大量超额认购,相当於国际发售项下初步可供认购发售股份总数的约33.4倍。
每股发售价定於26.3元,为上限定价(招股价介乎23.5元至26.3元),一手100股中签率为20%。该股将於明日(15日)挂牌上市。联席保荐人为高盛及中金公司。
公司预计,上市集资净额为39.02亿元,其中35%拟用於加强数据处理技术及机器学习算法等核心能力,及提升提供客户所需解决方案的能力;35%拟用於为业务运营提供资金及进一步进行业务扩张,包括为现有及新市场开发新的应用和解决方案以及在现有或新市场中销售及营销该等新应用程序及解决方案;20%拟用於通过战略合夥、投资及收购以进一步丰富生态系统;以及10%拟用於营运资金及一般企业用途。
公司引入八名基石投资者,包括OrbiMed Funds、加拿大退休金计划投资委员会及文莱投资局旗下Yaqut Sdn Bhd、腾讯(00700.HK)附属Tencent Mobility、嘉里控股旗下Velmar Company Limited、Matthews Funds、3W Fund Management及中国东方等,合共认购6,188.62万股股份,占全球发售完成後公司已发行股本的约6.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.